Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
CERO THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
23.12. | CERO THERAPEUTICS HOLDINGS, INC. - S-1, General form for registration of securities | 10 | SEC Filings | ||
09.12. | CERO THERAPEUTICS HOLDINGS, INC. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
06.12. | CERo Therapeutics appoints Chris Ehrlich CEO | 2 | Seeking Alpha | ||
06.12. | CERo Therapeutics Holdings, Inc.: CERo Therapeutics, Inc. Appoints Chris Ehrlich CEO | 81 | GlobeNewswire (Europe) | SOUTH SAN FRANCISCO, Calif, Dec. 06, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) ("CERo"), an innovative immunotherapy company seeking to advance the next generation... ► Artikel lesen | |
06.12. | CERO THERAPEUTICS HOLDINGS, INC. - 8-K, Current Report | - | SEC Filings | ||
27.11. | CERO THERAPEUTICS HOLDINGS, INC. - S-1, General form for registration of securities | 3 | SEC Filings | ||
25.11. | CERO THERAPEUTICS HOLDINGS, INC. - S-1/A, General form for registration of securities | 4 | SEC Filings | ||
20.11. | CERO THERAPEUTICS HOLDINGS, INC. - 10-Q/A, Quarterly Report | 2 | SEC Filings | ||
19.11. | CERO THERAPEUTICS HOLDINGS, INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
15.11. | CERo Therapeutics Holdings, Inc.: CERo Therapeutics, Inc. Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Its Lead Compound CER-1236 in Acute Myelogenous Leukemia | 215 | GlobeNewswire (Europe) | SOUTH SAN FRANCISCO, Calif, Nov. 15, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) ("CERo"), an innovative immunotherapy company seeking to advance the next generation... ► Artikel lesen | |
14.11. | CERO THERAPEUTICS HOLDINGS, INC. - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB | 15 | SEC Filings | ||
12.11. | CERO THERAPEUTICS HOLDINGS, INC. - 8-K, Current Report | 13 | SEC Filings | ||
11.11. | CERo Therapeutics Holdings, Inc.: CERo Therapeutics, Inc. Presents Preclinical Data Demonstrating CER-1236 Killing Ovarian Cancer Cell Lines Without Toxicity | 7 | GlobeNewswire (USA) | ||
01.11. | CERO THERAPEUTICS HOLDINGS, INC. - 8-K, Current Report | 7 | SEC Filings | ||
25.10. | Cero Therapeutics Faces NASDAQ Delisting Over Low Stock Price | 3 | Investing.com | ||
25.10. | Cero Therapeutics droht Delisting von der NASDAQ aufgrund niedriger Aktienkurse | 6 | Investing.com Deutsch | ||
22.10. | CERO THERAPEUTICS HOLDINGS, INC. - S-1/A, General form for registration of securities | 1 | SEC Filings | ||
21.10. | CERo Therapeutics files to sell 713.6M shares of common stock for holders | 1 | Seeking Alpha | ||
21.10. | CERO THERAPEUTICS HOLDINGS, INC. - S-1, General form for registration of securities | 1 | SEC Filings | ||
21.10. | CERO THERAPEUTICS HOLDINGS, INC. - 8-K, Current Report | - | SEC Filings |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
QIAGEN | 43,045 | -0,61 % | New Product Offerings Support QIAGEN's Shares Amid Currency Woes | ||
EVOTEC | 8,195 | -3,98 % | INDEX-MONITOR: Evotec und Auto1 im MDax - Befesa und Stabilus raus | ZUG (dpa-AFX) - Der Pharma-Wirkstoffforscher Evotec und der Online-Autohändler Auto1 kehren in den Index der mittelgroßen Börsenwerte, den MDax, zurück. Im Gegenzug steigen der Industrie-Recycler Befesa... ► Artikel lesen | |
QUANTUM-SI | 3,495 | -2,24 % | Pre-market Movers: Intrusion, SES AI, Solid Power, Quantum-Si, Rail Vision | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.55 A.M. ET).In the Green Intrusion Inc. (INTZ) is up over 380% at $2.16.
SES... ► Artikel lesen | |
TEMPUS AI | 34,070 | -2,99 % | Cathie Woods ARK kauft AMD und TEMPUS AI, verkauft ARCHER AVIATION | ||
BIONTECH | 108,50 | -1,00 % | Biontech und Pfizer zahlen für Vergleich in USA | MAINZ (dpa-AFX) - Der Impfstoffhersteller Biontech hat in den USA im Streit um Lizenzgebühren millionenschwere Vergleiche geschlossen. Insgesamt umgerechnet 1,2 Milliarden Euro werden das Unternehmen... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 6,820 | -7,71 % | Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules | Salt Lake City, Utah, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. ("Recursion") (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug... ► Artikel lesen | |
BB BIOTECH | 37,450 | -0,40 % | BB Biotech Erkenntnisse beim Lunch mit Vorständen | Ich war wie versprochen beim Investorenlunch von BB Biotech. Der scheidende Vorstandssprecher Dr. Daniel Koller führte seinen Nachfolger Dr. Christian Koch ein. Wie jedes Jahr hielt Vorstandssprecher... ► Artikel lesen | |
ADMA BIOLOGICS | 17,300 | -0,89 % | EWTX Yields Over 300% Returns, ADMA Records 200% Gains - Did You Strike While The Iron Is Hot? | WASHINGTON (dpa-AFX) - Biotech investing is a high-stakes game that may not suit the faint-hearted due to its inherent volatility. However, this sector can offer astronomical returns when investors... ► Artikel lesen | |
NUVALENT | 77,81 | -3,11 % | This Nuvalent Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday | ||
VALNEVA | 2,116 | -3,73 % | Valneva: Wilde Kursausschläge - Analysten sehen Vervielfachungspotenzial | Die Aktie von Valneva hat sich zuletzt von den 52-Wochen-Tiefs lösen können. Für frischen Rückenwind sorgte eine exklusive Lizenzvereinbarung mit dem weltgrößten Impfstoffproduzenten, dem Serum Institute... ► Artikel lesen | |
AVIDITY BIOSCIENCES | 28,610 | -5,01 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2024 Financial Results and Recent Highlights | Enrollment in global Phase 3 HARBOR study for del-desiran in DM1 is on track
Avidity initiated biomarker cohort for del-brax FORTITUDE study for FSHD; pursuing a... ► Artikel lesen | |
BAVARIAN NORDIC | 25,550 | -1,16 % | Unglaubliche Prognose für Montag setzt Bavarian Nordic Aktionäre unter Druck. Jetzt Sondermeldung lesen und Montag reagieren! | ||
ARCUTIS BIOTHERAPEUTICS | 14,215 | -0,63 % | Arcutis Biotherapeutics, Inc.: Arcutis Submits ZORYVE (roflumilast) Cream 0.05% Supplemental New Drug Application to the FDA for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis | ZORYVE cream 0.05% provided meaningful disease clearance and rapid reduction in itch in pivotal trialsRoflumilast cream was well tolerated and demonstrated a favorable safety and tolerability profile... ► Artikel lesen | |
ARCELLX | 77,74 | -1,68 % | Arcellx Stock Earns 82 Relative Strength Rating | ||
HUMACYTE | 5,350 | -2,73 % | Humacyte (NASDAQ:HUMA) Shares Up 6% - Here's What Happened |